1Cobleigh MA, Vogel CL, Tripathy N J, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overex- pressing metastatic breast cancer that progressed after chemotherapy for metastatic disease[J]. J Clin Oncol, 1999,17(9):2639.
2Slamon DJ,Leyland-Jones B,Shak S,et al. Use of chemo therapy plus a monoclonal antibody against HER2 for me tastatic breast cancer that overexpresses HER2[J]. N En gl J Med,2001,344(11):783.
3Extra JM,Cognetti F,Chan S,et al. Randomised phaseⅡtrial( M77001 ) of trastuzumab (Herceptin) plus docetaxel versus docetaxel alone, as first line therapy in patients with Her2 positive metastatic breast cancer[J]. Eur J Cancer, 2003,5 (Suppl 1):S202.
4Romond EH,Perez EA,Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2-positive breast cancer[J]. N Engl J Med,2005,353(16):1659.
5Piccarrt-Gebharl MJ, Procter M, Leyland-Jones B, et al Trastuzumab after adjuvant chemotherapy in HER2 posi tire breast cancer[J]. N Engl J Med, 2005,353(16):1680.
6Slamon D, Eiermann W, Robert N, ct al. Phase Ⅲ randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel,carboplatin and trastuzumab in HER-2 positive early breast cancer patients: BCIRG 006 study[J]. Breast Cancer Res Treat, 2005,94 : S5.
7Ciardiello F,Troiani T,Caputo F,et al. Phase Ⅱ study of gefitinib in combination with doctaxel as first-line therapy in metastatic breast cancer[J]. Br J Cancer, 2006,5(9):1038.
8Lyseng-Williamson KA, Robinson DM. Spotlight on bev acizumab in advanced colorectal cancer, breast cancer,and non small cell lung cancer[J]. Bio Drugs, 2006,20(3):193.
9Miller KD. E2100: A phase Ⅲ trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer[J]. Clin Breast Cancer, 2003,3(6):421.
10Jackson JG, Clair St , Sliwkowski P, et al. Blockade of epi-dermal growth factoror-heregulin dependent ErbB-2 activation with the anti-ErbB-2 monoclonal antibody 2C4 hal divergent downstream signaling and growth effeets[J]. Cancer Res, 2004,64:2601.
7Michael J. Overman M.D.,Paulo M. Hoff M.D., F.A.C.P.. EGFR-Targeted Therapies in Colorectal Cancer[J] 2007,Diseases of the Colon & Rectum(8):1259～1270
